synucleinopathies

YTX-465 is an inhibitor of both stearoyl-CoA desaturase(IC50s = 39 nM) and Ole1 (IC50s = 30.4 μM).

NPT200-11 is an orally bioavailable and brain penetrating inhibitor of accumulation of alpha-synuclein (ASYN) misfolding and aggregation. NPT200-11 can be used in studies about the underlying pathology of synucleinopathies including Parkinson's disease (PD), dementia with Lewy bodies (DLB) and Multiple Systems Atrophy (MSA).

ASN90 is a specific, orally active inhibitor of the O-GlcNAcase (OGA) enzyme, demonstrating an IC50 of 10.2 nM. It is utilized in the research of neurodegenerative disorders including tauopathies and α-synucleinopathies [1].

WAY-658674 is a bioactive molecule utilized in the research of amyloid diseases and synucleinopathies.

WAY-639299 is an investigational compound targeting amyloid disorders and synucleinopathies for research purposes.

WAY-622252 serves as an investigational compound for the research of amyloid diseases and synucleinopathies.

WAY-612453 is an active compound utilized in researching amyloid diseases and synucleinopathies.

WAY-385995 is an active compound utilized in the research of amyloidoses and synucleinopathies.

WAY-323756 is a research-active molecule utilized in the study of amyloid diseases and synucleinopathies.

WAY-311474 is an investigational compound targeting amyloid-related diseases and synucleinopathies.

WAY-309236 is an active compound utilized in researching amyloid diseases and synucleinopathies.

WAY-299375 is a research-active molecule targeting amyloid diseases and synucleinopathies.

WAY-232897 is an active compound utilized in the investigation of amyloid diseases and synucleinopathies.